The WHIM-like CXCR4 S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia

Leukemia

Volumn 29, Issue 1, 2015, Pages 169-176

  Cao, Y ^a,b   Hunter, Z R ^a,c   Liu, X ^a,b   Xu, L ^a   Yang, G ^a,b   Chen, J ^a   Patterson, C J ^a   Tsakmaklis, N ^a   Kanan, S ^a   Rodig, S ^b,d   Castillo, J J ^a,b   Treon, S P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CASPASE 3; CHEMOKINE RECEPTOR CXCR4; FLUDARABINE; IBRUTINIB; IDELALISIB; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLERIXAFOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; WART HYPOGAMMAGLOBULINEMIA INFECTION AND MYELOKATHEXIS PROTEIN; ANTINEOPLASTIC AGENT; CXCR4 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; BONE MARROW; CELL ENGINEERING; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; WALDENSTROEM MACROGLOBULINEMIA; WILD TYPE; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; WALDENSTROM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; RECEPTORS, CXCR4; WALDENSTROM MACROGLOBULINEMIA;

EID: 84920679727     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.187     Document Type: Article

References (25)

1. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012; 367: 826-833.
2. Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. The genomic landscape of Waldenstö m's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2013; 123: 1637-1646.
3. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121: 2051-2058.
4. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Pascutto C et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Walden-strom's macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121: 2522-2528.
5. Jimenez C, Sebastian E, Del Carmen Chillon M, Giraldo P, Mariano Hernández J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia. Leukemia 2013; 27: 1722-1728.
6. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E et al. MYD88 L265P mutation in Waldenstrom's macroglobulinemia. Blood 2013; 121: 4504-4511.
7. Roccaro A, Sacco A, Jiminez C, Maiso P, Moschetta M, Mishima Y et al. A novel activating mutation of CXCR4 plays a crucial role in Waldenstrom Macroglobulinemia biology. Blood 2013; 122: Abstract 272.
8. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Walden-strom's Macroglobulinemia. Blood 2014; 123: 2791-2796.
9. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 2013; 122: 1222-1232.
10. Dotta L, Tassone L, Badolato R. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome. Curr Mol Med 2011; 11: 317-325.
11. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768: 952-963.
12. Busillo JM, Amando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 2010; 285: 7805-7817.
13. Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X et al. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol 2013; 88: 463-471.
14. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008; 112: 150-158.
15. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-6296.
16. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012; 11: 873-887.
17. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009; 5: 484-493.
18. Treon SP, Tripsas C, Yang G, Cao Y, Xu L, Hunter ZR et al. A prospective multi-center study of the bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. Proc. Am Soc Hematol Blood 2013; 122: 251.
19. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007; 110: 4417-4426.
20. Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-1887.
21. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 2008; 111: 5068-5077.
22. McDermott DH, Lopez J, Deng F, Liu Q, Ojode T, Chen H et al. AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med 2011; 15: 2071-2081.
23. McDermott DH, Liu Q, Ulrick J, Kwatemaa N, Anaya-O'Brien S, Penzak SR et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011; 118: 4957-4962.
24. Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005; 105: 2449-2457.
25. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018.